Yousif Capital Management LLC reduced its stake in Mesa Laboratories, Inc. (NASDAQ:MLAB – Free Report) by 6.1% during the 3rd quarter, HoldingsChannel reports. The firm owned 2,553 shares of the medical instruments supplier’s stock after selling 165 shares during the period. Yousif Capital Management LLC’s holdings in Mesa Laboratories were worth $268,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Point72 Hong Kong Ltd purchased a new position in shares of Mesa Laboratories in the 1st quarter valued at approximately $27,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new position in shares of Mesa Laboratories in the 2nd quarter valued at approximately $41,000. Tower Research Capital LLC TRC grew its stake in shares of Mesa Laboratories by 235.2% in the 1st quarter. Tower Research Capital LLC TRC now owns 295 shares of the medical instruments supplier’s stock valued at $52,000 after purchasing an additional 207 shares during the last quarter. Amundi purchased a new position in shares of Mesa Laboratories in the 4th quarter valued at approximately $102,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Mesa Laboratories in the 3rd quarter valued at approximately $112,000. 91.06% of the stock is currently owned by hedge funds and other institutional investors.
Mesa Laboratories Stock Down 2.6 %
Shares of NASDAQ:MLAB opened at $91.62 on Thursday. Mesa Laboratories, Inc. has a 12-month low of $82.86 and a 12-month high of $206.36. The company has a fifty day simple moving average of $98.30 and a 200 day simple moving average of $109.45. The company has a current ratio of 2.96, a quick ratio of 2.13 and a debt-to-equity ratio of 0.44. The firm has a market cap of $493.83 million, a PE ratio of -654.38 and a beta of 0.81.
Mesa Laboratories Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 15th. Investors of record on Thursday, February 29th will be issued a dividend of $0.16 per share. The ex-dividend date of this dividend is Wednesday, February 28th. This represents a $0.64 dividend on an annualized basis and a yield of 0.70%. Mesa Laboratories’s dividend payout ratio is -457.11%.
Analyst Ratings Changes
A number of research firms recently weighed in on MLAB. StockNews.com began coverage on Mesa Laboratories in a research note on Thursday, October 5th. They issued a “hold” rating on the stock. Evercore ISI upgraded shares of Mesa Laboratories from an “in-line” rating to an “outperform” rating and raised their target price for the company from $100.00 to $125.00 in a report on Thursday, January 4th.
Insider Buying and Selling
In related news, SVP Brian David Archbold sold 1,500 shares of the firm’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $112.36, for a total value of $168,540.00. Following the completion of the transaction, the senior vice president now directly owns 558 shares of the company’s stock, valued at $62,696.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.20% of the stock is owned by insiders.
Mesa Laboratories Profile
Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions.
- Five stocks we like better than Mesa Laboratories
- Pros And Cons Of Monthly Dividend Stocks
- What is a bear market rally? Examples and how they work
- How to Invest in Renewable Energy
- 7 best bear market ETFs to battle a decline
- How to Invest in Fertilizer
- 10 best sugar stocks to buy now
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.